Neurologia i neurochirurgia polska最新文献

{"title":"Differences in prevalence of orthostatic hypotension between Parkinson's Disease motor subtypes.","authors":"Panteleimon Oikonomou, Jiri Koschel, Christian F Altmann, Wolfgang H Jost","doi":"10.5603/pjnns.104615","DOIUrl":"10.5603/pjnns.104615","url":null,"abstract":"","PeriodicalId":19132,"journal":{"name":"Neurologia i neurochirurgia polska","volume":" ","pages":"188-190"},"PeriodicalIF":2.9,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143516259","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Validation of the Polish version of the Movement Disorder Society Non-motor Rating Scale (MDS-NMS).","authors":"Joanna Siuda, Mateusz Toś, Tomasz Chmiela, Andrzej Bogucki, Barbara Borodziuk, Sławomir Budrewicz, Marek Dąbrowski, Marceli Gacan, Agata Gajos, Justyna Gawryluk, Piotr Janik, Justyna Kaczyńska, Ewa Koziorowska-Gawron, Jakub Malkiewicz, Ewa Papuć, Paulina Kaczmarska, Monika Rudzińska-Bar, Jarosław Sławek, Magdalena Wójcik-Pędziwiatr, Luowen Yu, Sheng Luo, Christopher Goetz, Glenn Stebbins, Pablo Martinez-Martin, Tiago Mestre, Alvaro Sanchez-Ferro, Monika Kurtis, Michelle Hyczy de Siqueira Tosin, Roberta Balestrino, Chi-Ying Roy Lin, Carmen Gasca-Salas","doi":"10.5603/pjnns.105278","DOIUrl":"10.5603/pjnns.105278","url":null,"abstract":"<p><strong>Aim of the study: </strong>We aimed to translate and validate the Polish version of the MDS-NMS and compare it with the original English version.</p><p><strong>Clinical rationale for the study: </strong>Non-motor symptoms (NMS) affect a significant portion of the Parkinson's disease (PD) patient population and may negatively impact their quality of life. Non-motor symptoms may contribute to an increased sense of illness among patients and to a greater burden upon their caregivers. It is therefore advisable to develop a Polish validation of a reference scale for diagnosing and assessing the severity of NMS.</p><p><strong>Material and methods: </strong>The MDS-NMS was translated into Polish by a third-party translation company experienced in the translation of rating scales and reviewed by the Polish Translation Validation Leader (JS). Following several rounds of review, the final translation received the approval of the MDS Translation Steering Committee for its use in Cognitive Pre-testing. The translated version of the MDS-NMS then underwent Cognitive Pre-testing, and the translation was subsequently modified based on the results. The approved version was considered to be the Official Working Document of the Polish MDS-NMS and was tested on 307 Polish PD patients recruited at movement disorder centers. Confirmatory and explanatory factor analyses were applied to determine whether the factor structure of the English version could be confirmed in the Polish version.</p><p><strong>Results: </strong>The overall factor structure of the Polish version was fairly consistent with that of the English version based on the high CFIs for all 14 subscales of the MDS-NMS in the confirmatory factor analysis (CFI ≥ 0.90). The Polish MDS-NMS was confirmed to share a common factor structure with the original English version.</p><p><strong>Conclusions: </strong>The availability of the Polish validation of the MDS-NMS scale will facilitate Polish research centers' participation in multi-center trials and clinical studies. Moreover, it will enable individual Polish researchers to compare their results collected on Polish PD patients more easily and confidently with those available worldwide. We are also convinced that the Polish version of MDS-NMS will prove useful in everyday clinical practice, facilitating the easier and more effective identification of NMS-related problems and the assessment of their severity.</p>","PeriodicalId":19132,"journal":{"name":"Neurologia i neurochirurgia polska","volume":" ","pages":"396-402"},"PeriodicalIF":2.6,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144789535","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Innovations in epilepsy treatment: pharmacological strategies and machine learning applications.","authors":"Natalia Chmielewska, Janusz Szyndler","doi":"10.5603/pjnns.103446","DOIUrl":"10.5603/pjnns.103446","url":null,"abstract":"<p><p>Epilepsy remains a significant global health challenge, with a substantial portion of patients experiencing inadequate seizure control despite existing therapeutic options. This review aimed at exploring recent advances in critical areas that, in the authors' opinion, hold promise for improving epilepsy treatment outcomes. Our paper briefly discusses issues related to gene therapy, including recently initiated clinical trials using this technique. Additionally, we explore the utility of machine learning techniques in diagnostics and predicting responses to antiseizure treatment. Next, we present novel drug delivery routes, such as intranasal and transdermal systems, which provide alternative methods to enhance drug efficacy and minimise side effects. Finally, we briefly characterise new antiseizure medication (ASMs) introduced within the European Union in the last five years, as well as ASMs currently in phase III clinical trials. In summary, this review highlights the potential impact of innovative treatments and technologies on epilepsy management.</p>","PeriodicalId":19132,"journal":{"name":"Neurologia i neurochirurgia polska","volume":" ","pages":"199-209"},"PeriodicalIF":2.9,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143720842","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Polish validation of Parkinson's Disease non-motor questionnaire and clinical use in real life PD patients.","authors":"Karolina Popławska-Domaszewicz, Jolanta Florczak-Wyspianska, Wojciech Ambrosius, K Ray Chaudhuri, Sławomir Michalak, Wojciech Kozubski","doi":"10.5603/pjnns.102113","DOIUrl":"10.5603/pjnns.102113","url":null,"abstract":"<p><strong>Aim of study: </strong>To perform a linguistic translation using validated methodology of the Parkinson's Disease Non-motor Questionnaire (NMSQuest) in a Polish Parkinson's Disease (PD) population, and apply the Polish NMSQuest to a real-life PD population.</p><p><strong>Clinical rationale for study: </strong>Non-motor symptoms are one of the key drivers of quality of life in PD patients and occur from the prodromal stage to the end palliative stage. Clinical recognition is crucial to manage these symptoms, and the PD NMSQuest is a globally used patient-completed validated PD-specific tool which helps to flag 30 common NMS in the clinic.</p><p><strong>Material and methods: </strong>Cognitive pretesting and linguistic translation were performed in 35 consecutive Polish PD patients using the translational programme recommended by the Movement Disorders Society. The validated and translated Polish version was then used in 70 consecutive PD patients (including the 35 original patients who performed the pretest) from outpatient clinics (43 males and 27 females). The mean age of the patients was 67.45 years (range 40-81) with a mean duration of PD of 12.32 years (range 2-24) and a median Hoehn and Yahr (HY) score of 3.</p><p><strong>Results: </strong>70 patients (mean age 67.45; mean duration of PD 12.32 years range 2-24; median HY score 3) provided 100% endorsement of the usefulness and need for using Polish NMSQuest using a cognitive pretest questionnaire. A subsequent study of the utility of the Polish NMSQuest showed it to be reliable across a large range of PD patients from 40-81 years and HY stages 1-4, with a mean declared NMS per patient of 6 across all stages of PD.</p><p><strong>Conclusions and clinical implications: </strong>The Polish version of the NMSQuest is reliable, valid and endorsed by Polish PD patients. Subsequent clinical use shows this to be a useful self- declaration flagging tool for NMS which needs to be captured in clinical visits so that clinical care includes management of NMS in PD.</p>","PeriodicalId":19132,"journal":{"name":"Neurologia i neurochirurgia polska","volume":" ","pages":"177-182"},"PeriodicalIF":2.9,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143795803","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Rowland Payne syndrome mimicking motor neuron disease.","authors":"Krzysztof Nieporęcki, Piotr Szczudlik, Marta Lipowska, Edyta Rosiak, Magdalena Kuźma-Kozakiewicz","doi":"10.5603/pjnns.103859","DOIUrl":"10.5603/pjnns.103859","url":null,"abstract":"","PeriodicalId":19132,"journal":{"name":"Neurologia i neurochirurgia polska","volume":" ","pages":"302-305"},"PeriodicalIF":2.9,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144004225","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Baló's concentric sclerosis as a rare stroke mimic.","authors":"Katarzyna Sawczyńska, Klaudia Kaczówka, Monika Marona, Matylda Gliniak, Maciej Motyl, Jeremiasz Jagiełła, Agnieszka Słowik","doi":"10.5603/pjnns.105737","DOIUrl":"10.5603/pjnns.105737","url":null,"abstract":"","PeriodicalId":19132,"journal":{"name":"Neurologia i neurochirurgia polska","volume":" ","pages":"434-437"},"PeriodicalIF":2.6,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144541472","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Severity and predictors of internalised stigma among people with epilepsy in Poland.","authors":"Piotr Świtaj, Paweł Grygiel, Nina Kożuch, Halina Sienkiewicz-Jarosz","doi":"10.5603/pjnns.103495","DOIUrl":"10.5603/pjnns.103495","url":null,"abstract":"<p><strong>Aim of study: </strong>This study was aimed at exploring the intensity and associated factors of internalised stigma (or self-stigma) among Polish patients diagnosed with epilepsy.</p><p><strong>Clinical rationale for study: </strong>People with chronic diseases are commonly stigmatised in society. Some patients tend also to self-stigmatise, i.e. apply to oneself, accept and internalise negative stereotypes about their condition, which can result in a variety of adverse health outcomes and an impaired quality of life.</p><p><strong>Material and methods: </strong>A total of 120 patients with epilepsy treated in the Institute of Psychiatry and Neurology in Warsaw were recruited. They were administered a set of self-report measures assessing internalised stigma, social network, material well-being, cultural capital, and level of disability. Socio-demographic and health-related data was also recorded. Hierarchical linear multiple regression analysis was used to identify factors independently related to the severity of internalised stigma.</p><p><strong>Results: </strong>66 (55.0%) participants reported experiencing minimal or no internalised stigma, 34 (28.3%) reported mild, 18 (15.0%) moderate, and two (1.7%) severe internalised stigma. In the final regression model, independent predictors of lesser internalised stigma turned out to be a larger and supportive social network (β = -0.36, p < 0.01) and greater cultural capital (β = -0.17, p < 0.05). Stronger internalised stigma was predicted when three or more antiseizure medications were used (β = 0.33, p < 0.01), and when there were higher levels of disability (β = 0.25, p < 0.01).</p><p><strong>Conclusions: </strong>Although only a minority of patients with epilepsy in our sample reported moderate or high levels of internalised stigma, this remains a major clinical and social problem. These research results highlight the importance of personal resources (such as a supportive social network and high cultural capital) as factors protecting against internalising epilepsy stigma. Also, the indicators of the severity of the disease (such as the number of antiseizure medications used and the degree of disability) have been predictive factors associated with greater vulnerability to the development of self-stigmatised identity.</p><p><strong>Clinical implications: </strong>In clinical practice, patients with epilepsy should be screened for their tendency to self-stigmatise. There is a need to devise effective interventions to target internalised stigma associated with epilepsy, and to incorporate them into comprehensive therapeutic programmes for patients with this diagnosis.</p>","PeriodicalId":19132,"journal":{"name":"Neurologia i neurochirurgia polska","volume":" ","pages":"231-239"},"PeriodicalIF":2.9,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144266862","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Long-term effect and reasons for switching and combining device-aided therapies in Parkinson's Disease.","authors":"Dejan Georgiev, Maja Trost","doi":"10.5603/pjnns.102858","DOIUrl":"10.5603/pjnns.102858","url":null,"abstract":"<p><strong>Introduction: </strong>In the advanced stages of Parkinson's disease (PD), when standard drug adjustments fail to sufficiently improve patients' quality of life, device-aided therapies (DATs) such as deep brain stimulation (DBS), continuous subcutaneous apomorphine infusion (CSAI), levodopa-carbidopa intestinal gel infusion (LCIG), levodopa-carbidopa-entacapone intestinal gel infusion, or continuous subcutaneous foslevodoa-foscarbidopa infusion are beneficial in the long run. However, sometimes patients need to switch or combine DATs due to either adverse events or loss of efficacy.</p><p><strong>Aim of study: </strong>The aim of this article was to summarise the existing data on the long-term efficacy and adverse events of DATs, and to review the data on the rationale and efficacy for switching or combining DATs in advanced PD.</p><p><strong>State of the art: </strong>A total of 50 studies on the long-term efficacy of DBS (N = 28), LCIG (N = 12), CSAI (N = 10) and 13 studies on switching and combining DATs were included in this review. Although the DATs show a favourable long-term effect on the main motor and non-motor symptoms of PD they all feature specific adverse events that need to be considered when deciding which DAT to offer to a particular patient. Occasionally, switching or combining DATs is recommended, e.g. if the first DAT shows inadequate symptom control, or due to adverse events. The choice of the second DAT depends above all on the main problems of the first DAT being correctly recognised.</p><p><strong>Clinical implications: </strong>DATs are a safe and long-term effective option for the treatment of advanced PD. Switching and/or combining DATs is recommended for patients in whom the first treatment option is not optimal.</p><p><strong>Future directions: </strong>Future studies are warranted to address the unresolved issues related to long-term efficacy, side effect profile and switching and combination of DATs in multicentric studies and using advanced analytical approaches such as machine learning.</p>","PeriodicalId":19132,"journal":{"name":"Neurologia i neurochirurgia polska","volume":" ","pages":"111-126"},"PeriodicalIF":2.9,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142952403","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Family report of Birk-Barel syndrome - a neurodevelopmental channelopathy with epigenetic signature.","authors":"Dorota Piekutowska-Abramczuk, Maria Jędrzejowska, Elżbieta Ciara, Dorota Jurkiewicz, Paulina Halat-Wolska, Marlena Młynek, Krystyna Chrzanowska, Rafał Płoski, Agnieszka Madej-Pilarczyk","doi":"10.5603/pjnns.104700","DOIUrl":"10.5603/pjnns.104700","url":null,"abstract":"","PeriodicalId":19132,"journal":{"name":"Neurologia i neurochirurgia polska","volume":" ","pages":"185-187"},"PeriodicalIF":2.9,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143502869","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Patterns of antiseizure medication use in pregnant women with epilepsy: a 24-year observation in Poland.","authors":"Joanna Jędrzejczak, Beata Majkowska-Zwolińska","doi":"10.5603/pjnns.102936","DOIUrl":"10.5603/pjnns.102936","url":null,"abstract":"<p><strong>Aim of study: </strong>The aim of this study was to examine trends in the usage of antiseizure medications (ASM) in pregnant women with epilepsy (WWE) in Poland across 24 years.</p><p><strong>Clinical rationale for study: </strong>Most WWE continue ASM treatment during pregnancy. Over recent decades, third-generation ASMs with different safety profiles have become available. Understanding the long-term trends could provide valuable information for improving clinical practice guidelines.</p><p><strong>Material and methods: </strong>The study is based on prospectively collected data from an institutional database of a tertiary epilepsy centre between 2000 and 2024. Data on ASM use during pregnancy was recorded at conception and each trimester. Trends in ASM use in monotherapy and polytherapy were analysed. The study included 1,454 completed pregnancies with a known outcome and a mean maternal age of 28.99 years.</p><p><strong>Results: </strong>WWE were exposed to 19 different ASMs in monotherapy or polytherapy. Lamotrigine (LTG), valproate (VPA), carbamazepine (CBZ) and levetiracetam (LEV) accounted for 82% of all ASMs. Between 2000 and 2024, there was a statistically significant decrease in the usage of CBZ (Exp(B) = 0.92; p < 0.001; 8% annually) and of VPA (Exp(B) = 0.95; p = 0.005, 5% annually) and an increase in the use of LTG (Exp(B) = 1.03; p = 0.086; 3% annually) and of LEV (Exp(B) = 1.19; p < 0.001; 19% annually). More than two-thirds of the women were on monotherapy, both at conception and throughout pregnancy. WWE not exposed to ASMs accounted for 13.9% at conception and 10.5% in all trimesters. There was a significant increase in the number of women receiving polytherapy across all trimesters over time (Exp(B) = 1.02; p = 0.052; 2% annually) and a decrease in untreated women across all trimesters over time (Exp(B) = 0.97; p = 0.033; 3% annually). The mode of treatment at conception did not change statistically over time.</p><p><strong>Conclusions/clinical implications: </strong>The use of specific ASMs h as c hanged s ignificantly in th e 21 st ce ntury, wi th a no table decrease in the usage of CBZ and VPA in favour of LEV and LTG. There is an increasing trend towards polytherapy across all trimesters, but not at the conception point.</p>","PeriodicalId":19132,"journal":{"name":"Neurologia i neurochirurgia polska","volume":" ","pages":"245-253"},"PeriodicalIF":2.9,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143409443","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}